HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinical, pathological and genetic characteristics of Perry disease-new cases and literature review.

AbstractBACKGROUND AND PURPOSE:
Perry disease (or Perry syndrome) is an autosomal dominant neurodegenerative disorder characterized by parkinsonism, neuropsychiatric symptoms, central hypoventilation, weight loss and distinct TDP-43 pathology. It is caused by mutations of the DCTN1 gene encoding an essential component of axonal transport. The objectives were to provide the current state of knowledge on clinical, pathological and genetic aspects of Perry disease, as well as practical suggestions for the management of the disease.
METHODS:
Data on new patients from New Zealand, Poland and Colombia were collected, including autopsy report. Also all of the published papers since the original work by Perry in 1975 were gathered and analyzed.
RESULTS:
Parkinsonism was symmetrical, progressed rapidly and was poorly responsive to L-Dopa; nonetheless, a trial with high doses of L-Dopa is warranted. Depression was severe, associated with suicidal ideations, and benefited from antidepressants and L-Dopa. Respiratory symptoms were the leading cause of death, and artificial ventilation or a diaphragm pacemaker prolonged survival. Weight loss occurred in most patients and was of multifactorial etiology. Autonomic dysfunction was frequent but underdiagnosed. There was a clinical overlap with other neurodegenerative disorders. An autopsy showed distinctive pallidonigral degeneration with TDP-43 pathology. Genetic testing provided evidence of a common founder for two families. There was striking phenotypic variability in DCTN1-related disorders. It is hypothesized that oligogenic or polygenic inheritance is at play.
CONCLUSIONS:
Perry disease and other DCTN1-related diseases are increasingly diagnosed worldwide. Relatively effective symptomatic treatments are available. Further studies are needed to pave the way toward curative/gene therapy.
AuthorsJarosław Dulski, Catalina Cerquera-Cleves, Lukasz Milanowski, Alexa Kidd, Emilia J Sitek, Audrey Strongosky, Ana María Vanegas Monroy, Dennis W Dickson, Owen A Ross, Jolanta Pentela-Nowicka, Jarosław Sławek, Zbigniew K Wszolek
JournalEuropean journal of neurology (Eur J Neurol) Vol. 28 Issue 12 Pg. 4010-4021 (12 2021) ISSN: 1468-1331 [Electronic] England
PMID34342072 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Review)
Copyright© 2021 European Academy of Neurology.
Chemical References
  • Dynactin Complex
Topics
  • Depression (complications)
  • Dynactin Complex (genetics)
  • Humans
  • Hypoventilation (complications, genetics, therapy)
  • Mutation
  • Parkinsonian Disorders (diagnosis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: